Brief: Transgene: Astrazeneca Has Exercised Its First License Option for An Invir.IO Oncolytic Virus

Transgene SA

15/12/2021 06:42

Dec 15 (Reuters) - Transgene SA  TRNG.PA :
    * TRANSGENE ANNOUNCES LICENSE OPTION EXERCISE BY ASTRAZENECA
FOR
AN ONCOLYTIC VIRUS GENERATED BY TRANSGENE’S INVIR.IO™ PLATFORM
    * TO RECEIVE $8 MILLION UPFRONT OPTION EXERCISE PAYMENT
    * TRANSGENE IS ALSO ELIGIBLE TO RECEIVE DEVELOPMENT,
REGULATORY
AND SALES-BASED MILESTONES PAYMENTS AS WELL AS A ROYALTY BASED
ON FUTURE COMMERCIAL SALES
    * TRANSGENE HAS AN IN-HOUSE PILOT MANUFACTURING CAPABILITY
THAT
ALLOWS IT TO PRODUCE GMP BATCHES OF INVIR.IO™ DRUG CANDIDATES
FOR CLINICAL DEVELOPMENT

Source text for Eikon:  ID:nBw8MQLQPa 
Further company coverage:  TRNG.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))